---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-050174"
form_type: "8-K"
ticker: "IVVD"
cik: "0001832038"
company_name: "Invivyd, Inc."
filed_at: "2022-02-23T23:59:59+00:00"
generated_at: "2026-06-27T05:37:26.234420+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Adagio CEO Tillman Gerngross resigns; COO David Hering appointed interim CEO

## Summary
- David Hering appointed interim CEO, effective immediately; will also remain Chief Operating Officer.
- Board initiated a formal CEO search for a candidate with commercial-stage experience.
- Outgoing CEO Tillman Gerngross co-founded company, raised over $800M, advanced ADG20 into global pivotal trials for COVID-19.
- Hering previously led Pfizer's mRNA global franchise and was President of North America Vaccines.

## SEC filing metadata
- accession: 0001193125-22-050174
- form_type: 8-K
- ticker: IVVD
- cik: 0001832038
- company_name: Invivyd, Inc.
- filed_at: 2022-02-23T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1832038/000119312522050174/0001193125-22-050174-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1832038/000119312522050174/d267907d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-050174
- JSON: https://secwatch.observer/filing/0001193125-22-050174.json
- Plain text: https://secwatch.observer/filing/0001193125-22-050174.txt

## Key facts
- Executive change
  Tillman U. Gerngross resigned as Chief Executive Officer and President at Invivyd, Inc..
  - Action: resigned
  - Role: Chief Executive Officer and President
  source text: On February 23, 2022, Tillman U. Gerngross, Ph.D. resigned as Chief Executive Officer and President of Adagio Therapeutics, Inc. (the “Company”) and as a member of the Board of Directors (the “Board”) of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1832038/000119312522050174/0001193125-22-050174-index.htm
- Executive change
  David Hering was appointed as Interim Chief Executive Officer at Invivyd, Inc..
  - Action: appointed
  - Role: Interim Chief Executive Officer
  source text: Following Dr. Gerngross’s resignation, on February 23, 2022, the Board appointed David Hering to serve as Interim Chief Executive Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1832038/000119312522050174/0001193125-22-050174-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.